Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine in Selenoprotein N-related Myopathy (SelNac)
NCT02505087Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of acetylcysteine in selenoprotein N-related myopathy (SELENON-RM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Ratio of reduced glutathione and oxidized glutathione in blood erythrocytes at 6 months. Started Sep 2015; status: terminated.
02
Drugs
acetylcysteine
03
Conditions
selenoprotein N-related myopathy (SELENON-RM)
Beyond the preview
Go deeper on NCT02505087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02505087.